With further advancements in computational and experimental methods, synergy between these fields will drive the development of next-generation PARP1 inhibitors, promoting revolutionary targeted cancer treatments and improved prognosis for breast cancer patients worldwide. The gene discussed is PARP1; the disease is cancer.